Form 4: Denali Therapeutics Director Jay T. Flatley Reports Acquisition of Shares and Stock Options

Director Jay T. Flatley reports acquisition of Denali Therapeutics shares through Restricted Stock Units (RSUs) and stock options.

Summary

• On May 31, 2024, Jay T. Flatley, a director of Denali Therapeutics Inc., reported acquiring 5,967 shares of common stock through Restricted Stock Units (RSUs) and 17,901 stock options.
• The RSUs vest upon the earlier of one year from the grant date or the day preceding the next annual meeting of stockholders.
• The stock options have an exercise price of $18.56 and also vest upon the earlier of one year from the grant date or the day preceding the next annual meeting of stockholders.
• Following these transactions, Flatley directly owns 10,183 shares of common stock, including 5,967 unvested RSUs, and indirectly owns 336,313 shares through The Flatley Family Trust.
• He also directly owns 17,901 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and stock options by a director is generally a positive sign, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future performance.
• The vesting schedule of the RSUs and stock options aligns with long-term value creation.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a focus on long-term performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Comparing Flatley's holdings to other directors in similar biotech companies would provide a benchmark for assessing the magnitude of his investment.
• Stock option grants are a common form of executive compensation in the biotech industry, and the vesting schedule is typical for aligning management incentives with shareholder value.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment.
• Employees may view the director's investment as a positive sign for the company's future.

Key Dates